Research and Development

Democratizing CAR-T with LNP Technology

We are actively developing innovative approaches to deliver affordable, safe, and effective NanoCAR Therapeutics, with the goal of significantly reducing treatment costs while maintaining the highest standards of quality and therapeutic efficacy.

Novelty and Advancement over Current State-of-the-Art

Current State-of-the-Art (Problem):

FDA-approved anti-FMC63 CAR-T cell therapies—including Breyanzi, Tecartus, Yescarta, and Kymriah—utilize FMC63-derived anti-FMC63 CAR constructs incorporating CD28 or 4-1BB co-stimulatory domains along with CD3ζ signaling domains.

These constructs rely on a limited antigen-binding interface and are capable of recognizing multiple CD19 isoforms (commonly reported as isoforms 1–7 and 9). However, variability in CD19 expression and alternative splicing can lead to incomplete target recognition, contributing to antigen escape–mediated relapse in treated patients.

Similarly, NexCAR19, developed by ImmunoACT in India, incorporates an enhanced binding architecture and demonstrates improved isoform coverage compared to first-generation constructs. Nevertheless, incomplete recognition of all CD19 variants may still permit residual antigen escape, highlighting the need for further optimization

Proposed Solution — LYSINE BIOTECH Innovation:

Lysine Biotech (India) has developed a novel human anti-CD19 CAR construct (huanti-CD19 CAR–CD27/4-1BB–CD3ζ) engineered to enhance target recognition and therapeutic performance.

This construct incorporates an optimized antigen-binding architecture with multiple cation–π interactions, enabling broad and robust recognition of human CD19 variants, and is designed to minimize antigen escape.

Novel Features:

Pan-isoform targeting: Designed for comprehensive recognition across CD19 variants, reducing the risk of isoform-driven antigen escape.

Enhanced binding affinity and specificity: Improved molecular interaction interface enables stronger and more selective binding to CD19.

Reduced relapse potential:Broader antigen coverage helps mitigate relapse associated with antigen escape mechanisms.

Improved therapeutic efficacy and persistence,incorporates: CD3ζ signaling domain (with optimized activation design), CD27 and 4-1BB co-stimulatory domains → Enhancing T-cell activation, expansion, and durability.

Read More About Products R&D Pipline

3.A patent is published in the USA (USPTO) and granted in India

1)Patent Title: Design and Composition of HuAnti-CD19 Chimeric Antigen Receptor Targeting B-Cell Malignancies Thereof

U.S. Patent No.: 8,897,292, U.S. Patent Application Number: US 2025/0250316 A1, Publication Date: August 7, 2025.Global Dossier.

2).Patent Title: Design and Composition of HuAnti-CD19 Chimeric Antigen Receptor Targeting B-Cell Malignancies Thereof

Indian Patent Granted No.: 567126, Indian Patent Application Number: 202341064804, Date of Issue: June 3, 2025.ipindia.gov.in.

3).Patent Title: DESIGN AND COMPOSITION OF LYSILIRAG-1 (GLP-1) DRUG FOR TREATING TYPE-2 DIABETES IN OBESE THEREOF

Indian Patent Granted No.: 586954, Indian Patent Application Number: 202441008291, Date of Issue: April 15, 2026.ipindia.gov.in.

4).Patent Title: DESIGN AND COMPOSITION OF SYNTHETIC PEPTIDE DRUG TO INHIBIT BETA-SECRETASE CLEAVAGE OF AMYLOID-BETA PRECURSOR PROTEIN THEREOF

Indian Patent Application IN 202441028428 (Patent Publication date 12/04/2024 and Request for Examination & Date 19-12-2025)ipindia.gov.in.

5).Patent Title: DESIGN AND COMPOSITION OF OLIGONUCLEOTIDES PRIMER SEQUENCES FOR DIAGNOSIS OF LEPTOSPIRA INTERROGANS AND APPLICATION FOR MRNA BASED HUMAN AND VETERINARY VACCINE AGAINST LEPTOSPIROSIS THEREOF

Indian Patent Application IN 202441031814 (Patent Publication date 26/04/2024)ipindia.gov.in.